Boltbody Immune-stimulating Antibody Conjugates: A New Class of Immuno-oncology Therapeutics
Time: 12:00 pm
day: Conference Day 2
Details:
- Immune Stimulating Antibody Conjugates (ISACs) provide unexpected biological advantages over the mixture of antibody and small molecule TLR7/8 agonist
- Treatment with ISACs elicits durable anti-tumor immunity and T cell-dependent immunological memory
- Next generation ISACs enable targeting of tumors with lower antigen expression
